Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

Hand Held DNA Sequencer

Larry H. Bernstein, MD, FCAP, Curator

LPBI

 

Point-of-Care DNA Sequencer Inching Closer to Widespread Use as Beta-Testers Praise Oxford Technologies’ Pocketsize, Portable Nanopore Device

November 4, 2015

MinION could help achieve NIH’s goal of $1,000 human genome sequencing and in remote clinics and outbreak zones shift testing away from medical laboratories

Point-of-care DNA sequencing  technology is edging ever closer to widespread commercial use as the Oxford Nanopore MinION sequencer  draws praise and registers successes in pre-release testing.

A pocketsize gene-sequencing machine such as the MinION could transform the marketplace by shifting DNA testing to remote clinics and outbreak zones while eliminating the need to return samples to clinical laboratories for analysis. Such devices also are expected to increase the need for trained genetic pathologists andmedical technologists.

After Much Anticipation, MinION Delivers on Promises

The MinION, produced by United Kingdom-based Oxford Nanopore Technologies, is a miniaturized instrument about the size of a USB memory stick that plugs directly into a PC or laptop computer’s USB port. Unlike bench-top sequencers, the MinION uses nanopore “strand sequencing” technology to deliver ultra-long-read-length single-molecule sequence data.

“The USB-powered sequencer contains thousands of wells, each containing nanopores—narrow protein channels that are only wide enough for a single strand of DNA. When DNA enters the channels, each base gives off a unique electronic signature that can be detected by the system, providing a readout of the DNA sequence,” reported

After several years of unfulfilled promises, Oxford began delivering the MinION in the spring of 2014 to researchers participating in its early access program called MAP . For a $1,000 access fee, participants receive a starter kit and may purchase consumable supplies. The current price for additional flow cells ranges from $900 for one to $500 per piece when purchased in 48-unit quantities.

 

Nick Loman, an Independent Research Fellow in the Institute for Microbiology and Infection at the University of Birmingham, UK, had questioned if MinION’s promise would ever be realized. But the USB-size sequencer won him over after he used it to detect Salmonella within 15 minutes in samples sent from a local hospital.

 

Loman received the MinION in May 2014 as part of the MAP program and quickly tested its usefulness. After using the device to sequence a strain of Pseudomonas aeruginosa, a common hospital-acquired infection (HAI), he next helped solve the riddle of an outbreak of Salmonella infection in a Birmingham hospital that had affected 30 patients and staff.

“The hospital wanted to understand quickly what was happening,” Loman stated. “But routine genome sequencing is quite slow. It usually takes weeks or even months to get information back.”

Using MinION, Loman detected Salmonella in some of the samples sent from the hospital in less than 15 minutes. Ultimately, the main source of the outbreak was traced to a German egg supplier.

“The MinION just blew me away,” Loman stated in Wired. “The idea that you could do sequencing on a sort of USB stick that you can chuck around does stretch credulity.”

Portable Sequencing Opens Up Intriguing Possibilities for Pathologists

In May 2015, Oxford released a second version of the device, the MinION MkI. According to the company website, the updated MinION is a “full production device featuring improvements of performance and ease of use,” such as improved temperature control and updated mechanism to engage the device with the consumable flow cells.

“The bench-top sequencers opened up the market to a certain degree,” Loman says. “You started seeing [them] in intensive research groups and in the clinic. But what if anyone could have this hanging off their key ring and go do sequencing? That’s an insane idea, and we don’t really know what it’s going to mean in terms of the potential applications. We’re very much at the start of thinking about what we might be able to do, if anyone can just sequence anything, anywhere they are.”

 

Joshua Quick, a PhD candidate at the University of Birmingham, UK believes Oxford Nanopore Technologies’ portable and inexpensive device will change the gene sequencing landscape.

 

Accuracy One Trade-off for Portability

Beta-testers have shown that the miniature device can read out relatively long stretches of genetic sequence with increasing accuracy, but according to the report in the journal Nature , the MinION MkI will need to correct several shortcomings found in the original sequencer:

• It is not practical to sequence large genomes with the device, with some experts estimating it would take a year for the original version to sequence the equivalent of a human genome.

• The machine has a high error rate compared with those of existing full-sized sequencers, misidentifying DNA sequence 5%–30% of the time.

• It also has difficulties reading sections of genome that contain long stretches of a single DNA base.

Yet researchers who have used the device remain enthusiastic about the future of this fourth-generation sequencing technique, which may have the potential to achieve the $1,000-per-human-genome goal set by the National Institutes of Health  (NIH).

“This is the democratization of sequencing,” Joshua Quick, a PhD candidate at the University of Birmingham, told Nature. “You don’t have to rely on expensive infrastructure and costly equipment.”

News accounts did not provide information about Oxford Nanopore’s plans to obtain an EU mark for its MinION device. That will be the next step to demonstrating that the device is ready for widespread clinical use. At the same time, clinical laboratory managers and pathologist should take note of the capabilities of the MinION MkI as described above. Researchers are already finding it useful to identify infectious diseases in clinical setting where other diagnostic methods have not yet identified the agent causing the infection.

Read Full Post »

Humanized Mice May Revolutionize Cancer Drug Discovery

Curator: Stephen J. Williams, Ph.D.

Humanized Mice May Revolutionize Cancer Drug Discovery

Word Cloud by Zach Day

Decades ago cancer research and the process of oncology drug discovery was revolutionized by the development of mice deficient in their immune system, allowing for the successful implantation of human-derived tumors. The ability to implant human tumors without rejection allowed researchers to study how the kinetics of human tumor growth in its three-dimensional environment, evaluate potential human oncogenes and drivers of oncogenesis, and evaluate potential chemotherapeutic therapies. Indeed, the standard preclinical test for antitumor activity has involved the subcutaneous xenograft model in immunocompromised (SCID or nude athymic) mice. More detail is given in the follow posts in which I describe some early pioneers in this work as well as the development of large animal SCID models:

Heroes in Medical Research: Developing Models for Cancer Research

The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research

The SCID Pig II: Researchers Develop Another SCID Pig, And Another Great Model For Cancer Research

This strategy (putting human tumor cells into immunocompromised mice and testing therapeutic genes and /or compounds) has worked extremely well for most cytotoxic chemotherapeutics (those chemotherapeutic drugs with mechanisms of action related to cell kill, vital cell functions, and cell cycle). For example the NCI 60 panel of human tumor cell lines has proved predictive for the chemosensitivity of a wide range of compounds.

Even though the immunocompromised model has contributed greatly to the chemotherapeutic drug discovery process. using these models to develop the new line of immuno-oncology products has been met with challenges three which I highlight below with curated database of references and examples.

From a practical standpoint development of a mouse which can act as a recipient for human tumors yet have a humanized immune system allows for the preclinical evaluation of antitumoral effect of therapeutic antibodies without the need to use neutralizing antibodies to the comparable mouse epitope,   thereby reducing the complexity of the study and preventing complications related to pharmacokinetics.

Champions Oncology Files Patents for Use of PDX Platform in Immune-Oncology

Hackensack, NJ – August 17, 2015 – Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it has filed two patent applications with the United States Patent and Trademark Office (USPTO) relating to the development and use of mice with humanized immune systems to test immune-oncology drugs and therapeutic cancer vaccines.

Dr. David Sidransky, the founder and Chairman of Champions Oncology commented, “Drug development ‎in the immune-oncology space is fundamentally changing our approach to cancer treatment. These patents represent potentially invaluable tools for developing and personalizing immune therapy based on cutting edge sequence analysis, bioinformatics and our unique in vivo models.”

Joel Ackerman, Chief Executive Officer of Champions Oncology stated, “Developing intellectual property related to our Champions TumorGraft® platform has been an important component of strategy. The filing of these patents is an important milestone in leveraging our research and development investment to expand our platform and create proprietary tools for use by our pharmaceutical partners. We continue to look for additional revenue streams to supplement our fee-for-service business and we believe these patents will help us capture more of the value we create for our customers in the future.”

The first patent filing covers the methodology used by the Company to create a mouse model, containing a humanized immune system and a human tumor xenograft, which is capable of testing the efficacy of immune-oncology agents, both as single agents and in combination with anti-neoplastic drugs. The second patent filing relates to the detection of neoantigens and their role in the development of anti-cancer vaccines.

Keren Pez, Chief Scientific Officer, explained, “In the last few years, there has been a significant increase in cancer research that focuses on exploring the power of the human immune system to attack tumors. However, it’s challenging to test immune-oncology agents in traditional animal models due to the major differences between human and murine immune systems. The Champions ImmunoGraft™ platform has the unique ability of mimicking a human adaptive immune response in the mice, which allows us to specifically evaluate a variety of cancer therapeutics that modulate human immunity.

“Therapeutic vaccines that trigger the immune system to mount a response against a growing tumor are another area of intense interest. The development of an effective vaccine remains challenging but has an outstanding curative potential. Tumors harbor mutations in DNA that result in the translation of aberrant proteins. While these proteins have the potential to provoke an immune response that destructs early-stage cancer development, often the immune response becomes insufficient. Vaccines can trigger it by proactively challenging the system with these specific mutated peptides. Nevertheless, developing anti-cancer vaccines that effectively inhibit tumor growth has been complicated, partially due to challenges in finding the critical mutations, among others difficulties. With the more recent advances in genome sequencing, it’s now possible to identify tumor-specific antigens, or neoantigens, that naturally develop as an individual’s tumor grows and mutates,” she continued.

Traumatic spinal cord injury in mice with human immune systems.

Carpenter RS, Kigerl KA, Marbourg JM, Gaudet AD, Huey D, Niewiesk S, Popovich PG.

Exp Neurol. 2015 Jul 17;271:432-444. doi: 10.1016/j.expneurol.2015.07.011. [Epub ahead of print]

Inflamm Bowel Dis. 2015 Jul;21(7):1652-73. doi: 10.1097/MIB.0000000000000446.

Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Koboziev I1, Jones-Hall Y, Valentine JF, Webb CR, Furr KL, Grisham MB.

Author information

Abstract

Animal models of disease have been used extensively by the research community for the past several decades to better understand the pathogenesis of different diseases and assess the efficacy and toxicity of different therapeutic agents. Retrospective analyses of numerous preclinical intervention studies using mouse models of acute and chronic inflammatory diseases reveal a generalized failure to translate promising interventions or therapeutics into clinically effective treatments in patients. Although several possible reasons have been suggested to account for this generalized failure to translate therapeutic efficacy from the laboratory bench to the patient’s bedside, it is becoming increasingly apparent that the mouse immune system is substantially different from the human. Indeed, it is well known that >80 major differences exist between mouse and human immunology; all of which contribute to significant differences in immune system development, activation, and responses to challenges in innate and adaptive immunity. This inconvenient reality has prompted investigators to attempt to humanize the mouse immune system to address important human-specific questions that are impossible to study in patients. The successful long-term engraftment of human hematolymphoid cells in mice would provide investigators with a relatively inexpensive small animal model to study clinically relevant mechanisms and facilitate the evaluation of human-specific therapies in vivo. The discovery that targeted mutation of the IL-2 receptor common gamma chain in lymphopenic mice allows for the long-term engraftment of functional human immune cells has advanced greatly our ability to humanize the mouse immune system. The objective of this review is to present a brief overview of the recent advances that have been made in the development and use of humanized mice with special emphasis on autoimmune and chronic inflammatory diseases. In addition, we discuss the use of these unique mouse models to define the human-specific immunopathological mechanisms responsible for the induction and perpetuation of chronic gut inflammation.

J Immunother Cancer. 2015 Apr 21;3:12. doi: 10.1186/s40425-015-0056-2. eCollection 2015.

Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model.

Roth MD1, Harui A1.

Author information

Abstract

BACKGROUND:

The complex interactions that occur between human tumors, tumor infiltrating lymphocytes (TIL) and the systemic immune system are likely to define critical factors in the host response to cancer. While conventional animal models have identified an array of potential anti-tumor therapies, mouse models often fail to translate into effective human treatments. Our goal is to establish a humanized tumor model as a more effective pre-clinical platform for understanding and manipulating TIL.

METHODS:

The immune system in NOD/SCID/IL-2Rγnull (NSG) mice was reconstituted by the co-administration of human peripheral blood lymphocytes (PBL) or subsets (CD4+ or CD8+) and autologous human dendritic cells (DC), and animals simultaneously challenged by implanting human prostate cancer cells (PC3 line). Tumor growth was evaluated over time and the phenotype of recovered splenocytes and TIL characterized by flow cytometry and immunohistochemistry (IHC). Serum levels of circulating cytokines and chemokines were also assessed.

RESULTS:

A tumor-bearing huPBL-NSG model was established in which human leukocytes reconstituted secondary lymphoid organs and promoted the accumulation of TIL. These TIL exhibited a unique phenotype when compared to splenocytes with a predominance of CD8+ T cells that exhibited increased expression of CD69, CD56, and an effector memory phenotype. TIL from huPBL-NSG animals closely matched the features of TIL recovered from primary human prostate cancers. Human cytokines were readily detectible in the serum and exhibited a different profile in animals implanted with PBL alone, tumor alone, and those reconstituted with both. Immune reconstitution slowed but could not eliminate tumor growth and this effect required the presence of CD4+ T cell help.

CONCLUSIONS:

Simultaneous implantation of human PBL, DC and tumor results in a huPBL-NSG model that recapitulates the development of human TIL and allows an assessment of tumor and immune system interaction that cannot be carried out in humans. Furthermore, the capacity to manipulate individual features and cell populations provides an opportunity for hypothesis testing and outcome monitoring in a humanized system that may be more relevant than conventional mouse models.

Methods Mol Biol. 2014;1213:379-88. doi: 10.1007/978-1-4939-1453-1_31.

A chimeric mouse model to study immunopathogenesis of HCV infection.

Bility MT1, Curtis A, Su L.

Author information

Abstract

Several human hepatotropic pathogens including chronic hepatitis C virus (HCV) have narrow species restriction, thus hindering research and therapeutics development against these pathogens. Developing a rodent model that accurately recapitulates hepatotropic pathogens infection, human immune response, chronic hepatitis, and associated immunopathogenesis is essential for research and therapeutics development. Here, we describe the recently developed AFC8 humanized liver- and immune system-mouse model for studying chronic hepatitis C virus and associated human immune response, chronic hepatitis, and liver fibrosis.

PMID:

25173399

[PubMed – indexed for MEDLINE]

PMCID:

PMC4329723

Free PMC Article

Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients.

Werner-Klein M, Proske J, Werno C, Schneider K, Hofmann HS, Rack B, Buchholz S, Ganzer R, Blana A, Seelbach-Göbel B, Nitsche U, Männel DN, Klein CA.

PLoS One. 2014 May 15;9(5):e97860. doi: 10.1371/journal.pone.0097860. eCollection 2014.

From 2015 AACR National Meeting in Philadelphia

LB-050: Patient-derived tumor xenografts in humanized NSG mice: a model to study immune responses in cancer therapy
Sunday, Apr 19, 2015, 3:20 PM – 3:35 PM
Minan Wang1, James G. Keck1, Mingshan Cheng1, Danying Cai1, Leonard Shultz2, Karolina Palucka2, Jacques Banchereau2, Carol Bult2, Rick Huntress2. 1The Jackson Laboratory, Sacramento, CA; 2The Jackson Laboratory, Bar Harbor, ME

References

  1. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. J Natl Cancer Inst. 1989;81:1088–1092. [PubMed]
  2. Shi LM, Fan Y, Lee JK, Waltham M, Andrews DT, Scherf U, Paull KD, Weinstein JN. J Chem Inf Comput Sci. 2000;40:367–379. [PubMed]
  3. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. J Natl Cancer Inst. 1991;83:757–766. [PubMed]
  4. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294–1300. [PubMed]
  5. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat. 2009;3:1309–1334.
  6. Carlson, B. Putting Oncology Patients at Risk Biotechnol Healthc. 2012 Fall; 9(3): 17–21.
  7. Salter KH, Acharya CR, Walters KS, et al. An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer. Ouchi T, ed. PLoS ONE. 2008;3(4):e1908. NOTE RETRACTED PAPER

Other posts on this site on Animal Models, Disease and Cancer Include:

Heroes in Medical Research: Developing Models for Cancer Research

Guidelines for the welfare and use of animals in cancer research

Model mimicking clinical profile of patients with ovarian cancer @ Yale School of Medicine

Vaccines, Small Peptides, aptamers and Immunotherapy [9]

Immunotherapy in Cancer: A Series of Twelve Articles in the Frontier of Oncology by Larry H Bernstein, MD, FCAP

Mouse With ‘Humanized Version’ Of Human Language Gene Provides Clues To Language Development

The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research

The SCID Pig II: Researchers Develop Another SCID Pig, And Another Great Model For Cancer Research

Read Full Post »

Three-day Course by UC San Diego’s Rady School of Management Center for Executive Development: Biotech Demystified: The Science Behind Business

Reporter: Aviva Lev-Ari, PhD, RN

 

 

Biotech Demystified: The Science Behind Business

 

 

Joanna Skubisz

Associate, Communications Planning w firmie Underscore Marketing LLC

 

 

This 3-day hands-on educational program on September 14, 15 & 16, 2015 offered by UC San Diego’s Rady School of Management Center for Executive Development is designed specifically for non-scientist business professionals in the Biotech, Pharma and Life Science industries. It provides participants with a practical understanding of the basic science powering their businesses, giving them the essential tools needed to succeed in today’s life science industries. It provides executives, investors and decision makers with a practical understanding of the basic science powering the biotechnology and pharmaceutical industries.

San Diego is one of the nation’s top-ranking biotech centers and is home to more than 500 biotech and four major research institutions. Biotech Demystified is offered through the Rady School of Management Center for Executive Development in collaboration with UC San Diego’s Division of Biological Sciences and Skaggs School of Pharmacy and Pharmaceutical Sciences.

Led by a rich collection of biomedical research faculty from UC San Diego, attendees will dive into a deep pool of contemporary bioscience that include the following topics:

• Science fundamentals

• Cell biology and molecular biology

• Stem cell research

• Personalized medicine and drug delivery

• Cancer and therapeutic approaches

• Biosimilars and biobetters

• Genetic and genome mapping

• Hands-on lab experience with DNA testing

View the course details & register here http://bit.ly/BiotechDemystified.

SOURCE

From: Professionals in the Pharmaceutical and Biotech Industry <groups-noreply@linkedin.com>

Date: Wednesday, August 5, 2015 at 12:32 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: [New announcement] Biotech Demystified: The Science Behind Business

Read Full Post »

Israel’s Chief Scientist on Mastering the Art of Public-Private Partnership

Reporter: Aviva Lev-Ari, PhD, RN

 

Israel’s Chief Scientist on Mastering the Art of Public-Private Partnership.

This article was published by Gil Press in Forbes.

Read Full Post »

Emerging Life Science Companies in Massachusetts

Reporter: Aviva Lev-Ari, PhD, RN

<iframe src=”https://www.google.com/maps/d/embed?mid=z5Ov-Kra040U.krW1YdS8lvVE&#8221; width=”640″ height=”480″>

https://www.google.com/maps/d/embed?&mid=1-wGKsCdFVi9EkAzwxnJaBN87vy8&ll=42.333255085843746%2C-71.12668330124322&z=11

 

SOURCE

Venture Development Center
University of Massachusetts Boston
Wheatley Hall, Third Floor
100 Morrissey Blvd. Boston, MA 02125-3393
vdc@umb.edu

Read Full Post »

Protecting Your Biotech IP and Market Strategy: Notes from Life Sciences Collaborative 2015 Meeting

 

Protecting Your Biotech IP and Market Strategy: Notes from Life Sciences Collaborative 2015 Meeting

Reporter: Stephen J. Williams, PhD

Article ID #169: Protecting Your Biotech IP and Market Strategy: Notes from Life Sciences Collaborative 2015 Meeting. Published on 3/11/2015

WordCloud Image Produced by Adam Tubman

Achievement Beyond Regulatory Approval – Design for Commercial Success

philly2nightStephen J. Williams, Ph.D.: Reporter

The Mid-Atlantic group Life Sciences Collaborative, a select group of industry veterans and executives from the pharmaceutical, biotechnology, and medical device sectors whose mission is to increase the success of emerging life sciences businesses in the Mid-Atlantic region through networking, education, training and mentorship, met Tuesday March 3, 2015 at the University of the Sciences in Philadelphia (USP) to discuss post-approval regulatory issues and concerns such as designing strong patent protection, developing strategies for insurance reimbursement, and securing financing for any stage of a business.

The meeting was divided into three panel discussions and keynote speech:

  1. Panel 1: Design for Market Protection– Intellectual Property Strategy Planning
  2. Panel 2: Design for Market Success– Commercial Strategy Planning
  3. Panel 3: Design for Investment– Financing Each Stage
  4. Keynote Speaker: Robert Radie, President & CEO Egalet Corporation

Below are Notes from each PANEL Discussion:

For more information about the Life Sciences Collaborative SEE

Website: http://www.lifesciencescollaborative.org/

Or On Facebook

Or On Twitter @LSCollaborative

Panel 1: Design for Market Protection; Intellectual Property Strategy Planning

Take-home Message: Developing a very strong Intellectual Property (IP) portfolio and strategy for a startup is CRITICALLY IMPORTANT for its long-term success. Potential investors, partners, and acquirers will focus on the strength of a startup’s IP so important to take advantage of the legal services available. Do your DUE DIGILENCE.

Panelists:

John F. Ritter, J.D.., MBA; Director Office Tech. Licensing Princeton University

Cozette McAvoy; Senior Attorney Novartis Oncology Pharma Patents

Ryan O’Donnell; Partner Volpe & Koenig

Panel Moderator: Dipanjan “DJ” Nag, PhD, MBA, CLP, RTTP; President CEO IP Shaktl, LLC

Notes:

Dr. Nag:

  • Sometimes IP can be a double edged sword; e.g. Herbert Boyer with Paul Berg and Stanley Cohen credited with developing recombinant technology but they did not keep the IP strict and opened the door for a biotech revolution (see nice review from Chemical Heritage Foundation).
  • Naked patent licenses are most profitable when try to sell IP

John Ritter: Mr. Ritter gave Princeton University’s perspective on developing and promoting a university-based IP portfolio.

  • 30-40% of Princeton’s IP portfolio is related to life sciences
  • Universities will prefer to seek provisional patent status as a quicker process and allows for publication
  • Princeton will work closely with investigators to walk them through process – Very Important to have support system in place INCLUDING helping investigators and early startups establish a STRONG startup MANAGEMENT TEAM, and making important introductions to and DEVELOPING RELATIONSHIOPS with investors, angels
  • Good to cast a wide net when looking at early development partners like pharma
  • Good example of university which takes active role in developing startups is University of Pennsylvania’s Penn UPstart program.
  • Last 2 years many universities filing patents for startups as a micro-entity

Comment from attendee: Universities are not using enough of their endowments for purpose of startups. Princeton only using $500,00 for accelerator program.

Cozette McAvoy: Mrs. McAvoy talked about monetizing your IP from an industry perspective

  • Industry now is looking at “indirect monetization” of their and others IP portfolio. Indirect monetization refers to unlocking the “indirect value” of intellectual property; for example research tools, processes, which may or may not be related to a tangible product.
  • Good to make a contractual bundle of IP – “days of the $million check is gone”
  • Big companies like big pharma looks to PR (press relation) buzz surrounding new technology, products SO IMPORTANT FOR STARTUP TO FOCUS ON YOUR PR

Ryan O’Donnell: talked about how life science IP has changed especially due to America Invests Act

  • Need to develop a GLOBAL IP strategy so whether drug or device can market in multiple countries
  • Diagnostics and genes not patentable now – Major shift in patent strategy
  • Companies like Unified Patents can protect you against the patent trolls – if patent threatened by patent troll (patent assertion entity) will file a petition with the USPTO (US Patent Office) requesting institution of inter partes review (IPR); this may cost $40,000 BUT WELL WORTH the money – BE PROACTIVE about your patents and IP

Panel 2: Design for Market Success; Commercial Strategy Planning

Take-home Message: Commercial strategy development is defined market facing data, reimbursement strategies and commercial planning that inform labeling requirements, clinical study designs, healthcare economic outcomes and pricing targets. Clarity from payers is extremely important to develop any market strategy. Develop this strategy early and seek advice from payers.

Panelists:

David Blaszczak; Founder, Precipio Health Strategies

Terri Bernacchi, PharmD, MBA; Founder & President Cambria Health Advisory Professionals

Paul Firuta; President US Commercial Operations, NPS Pharma

 

Panel Moderator: Matt Cabrey; Executive Director, Select Greater Philadelphia

 

Notes:

David Blaszczak:

  • Commercial payers are bundling payment: most important to get clarity from these payers
  • Payers are using clinical trials to alter marketing (labeling) so IMPORTANT to BUILD LABEL in early clinical trial phases (phase I or II)
  • When in early phases of small company best now to team or partner with a Medicare or PBM (pharmacy benefit manager) and payers to help develop and spot tier1 and tier 2 companies in their area

Terri Bernacchi:

  • Building relationship with the payer is very important but firms like hers will also look to patients and advocacy groups to see how they respond to a given therapy and decrease the price risk by bundling
  • Value-based contracting with manufacturers can save patient and payer $$
  • As most PBMs formularies are 80% generics goal is how to make money off of generics
  • Patent extension would have greatest impact on price, value

Paul Firuta:

  • NPS Pharma developing a pharmacy benefit program for orphan diseases
  • How you pay depends on mix of Medicare, private payers now
  • Most important change which could affect price is change in compliance regulations

Panel 3: Design for Investment; Financing Each Stage

Take-home Message: VC is a personal relationship so spend time making those relationships. Do your preparation on your value and your market. Look to non-VC avenues: they are out there.

Panelists:

Ting Pau Oei; Managing Director, Easton Capital (NYC)

Manya Deehr; CEO & Founder, Pediva Therapeutics

Sanjoy Dutta, PhD; Assistant VP, Translational Devel. & Intl. Res., Juvenile Diabetes Research Foundation

 

Panel Moderator: Shahram Hejazi, PhD; Venture Partner, BioAdvance

  • In 2000 his experience finding 1st capital was what are your assets; now has changed to value

Notes:

Ting Pau Oei:

  • Your very 1st capital is all about VALUE– so plan where you add value
  • Venture Capital is a PERSONAL RELATIONSHIP
  • 1) you need the management team, 2) be able to communicate effectively                  (Powerpoint, elevator pitch, business plan) and #1 and #2 will get you important 2nd Venture Capital meeting; VC’s don’t decide anything in 1st meeting
  • VC’s don’t normally do a good job of premarket valuation or premarket due diligence but know post market valuation well
  • Best advice: show some phase 2 milestones and VC will knock on your door

Manya Deehr:

  • Investment is more niche oriented so find your niche investors
  • Define your product first and then match the investors
  • Biggest failure she has experienced: companies that go out too early looking for capital

Dr. Dutta: funding from a non-profit patient advocacy group perspective

  • Your First Capital: find alliances which can help you get out of “valley of death
  • Develop a targeted product and patient treatment profile
  • Non-profit groups ask three questions:

1) what is the value to patients (non-profits want to partner)

2) what is your timeline (we can wait longer than VC; for example Cystic Fibrosis Foundation waited long time but got great returns for their patients with Kalydeco™)

3) when can we see return

  • Long-term market projections are the knowledge gaps that startups have (the landscape) and startups don’t have all the competitive intelligence
  • Have a plan B every step of the way

Other posts on this site related to Philadelphia Biotech, Startup Funding, Payer Issues, and Intellectual Property Issues include:

PCCI’s 7th Annual Roundtable “Crowdfunding for Life Sciences: A Bridge Over Troubled Waters?” May 12 2014 Embassy Suites Hotel, Chesterbrook PA 6:00-9:30 PM
The Vibrant Philly Biotech Scene: Focus on KannaLife Sciences and the Discipline and Potential of Pharmacognosy
The Vibrant Philly Biotech Scene: Focus on Computer-Aided Drug Design and Gfree Bio, LLC
The Vibrant Philly Biotech Scene: Focus on Vaccines and Philimmune, LLC
The Bioscience Crowdfunding Environment: The Bigger Better VC?
Foundations as a Funding Source
Venture Capital Funding in the Life Sciences: Phase4 Ventures – A Case Study
10 heart-focused apps & devices are crowdfunding for American Heart Association’s open innovation challenge
Funding, Deals & Partnerships
Medicare Panel Punts on Best Tx for Carotid Plaque
9:15AM–2:00PM, January 27, 2015 – Regulatory & Reimbursement Frameworks for Molecular Testing, LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA
FDA Commissioner, Dr. Margaret A. Hamburg on HealthCare for 310Million Americans and the Role of Personalized Medicine
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers
Litigation on the Way: Broad Institute Gets Patent on Revolutionary Gene-Editing Method
The Patents for CRISPR, the DNA editing technology as the Biggest Biotech Discovery of the Century

 

 

Read Full Post »

ANNOUNCEMENT

REAL TIME Coverage for the Press of MassBio 2015 Annual Meeting, March 26-27, 2015, Royal Sonesta Hotel, Cambridge, MA

by

Leaders in Pharmaceutical Business Intelligence

LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE

LPBI-Logo

will cover for the Scientific and Business Press in REAL TIME the MassBio 2015 Annual Meeting, March 26-27, 2015, Royal Sonesta Hotel, Cambridge, MA

 AGENDA

http://pharmaceuticalintelligence.com/2015/01/13/massbio-2015-annual-meeting-march-26-27-2015-royal-sonesta-hotel-cambridge-ma/

 

Dr. Lev-Ari will be in attendance on 3/26/2015 and 3/27/2015

 

Venture Overview Updated in New Company Page on LinkedIn: Leaders in Pharmaceutical Business Intelligence

http://pharmaceuticalintelligence.com/2015/03/07/venture-overview-updated-on-new-company-page-on-linkedin-leaders-in-pharmaceutical-business-intelligence/

 

ANNOUNCEMENT

at MassBio 2015 Annual Meeting, March 26-27, 2015, Royal Sonesta Hotel, Cambridge, MA

Forthcoming e-Books on Amazon-Kindle.com

by Experts, Authors, Writers of

LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE

Our Team

http://pharmaceuticalintelligence.com/contributors-biographies/

onepage series BCDE covers

 

onepageCVDseriesAflyervol1-4

 

Read Full Post »

Biobanking Congress 2015, Toronto, InterContinental Toronto Centre, July 14-16, 2015

Reporter: Aviva Lev-Ari, PhD, RN

 

FINAL AGENDA

 

Cambridge Healthtech Institute’s Seventh International Leaders in Biobanking Congress: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge biomedical research.

KEYNOTE SESSION: IT TAKES A VILLAGE

The Complexity of Pathologist Responsibilities as Custodians of Biospecimens

Sylvia L. Asa, M.D., Ph.D., Pathologist-in-Chief, Medical Director, Laboratory Medicine Program, University Health Network; Lakeridge Health &

Womens College Hospital; Senior Scientist, Ontario Cancer Institute; Professor, Laboratory Medicine & Pathobiology, University of Toronto

Discovery and Implementation Using EHR-Linked Biobanks: The eMERGE Experience

Rex L. Chisholm, Ph.D., Vice Dean, Scientific Affairs and Graduate Education; Adam and Richard T. Lind Professor, Medical Genetics, Northwestern

University Feinberg School of Medicine

Preparing Research Samples for Future Use: Innovative Methods for Assessing Functional Quality Control and Biobanking Best Practices

Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

Generating Comprehensive Standard Operating Procedures for a Biorepository Network – The CTRNet Experience

Brent Schacter, M.D., FRCPC, Principal Investigator, CTRNet; Professor, Department of Internal Medicine, Section of Hematology/

Oncology, College of Medicine, University of Manitoba/CancerCare Manitoba

MAINTAINING A QUALITY BIOBANK

Development and Implementation of a National Biospecimen Collection Network in a Community Hospital System

Jeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Inventory Management; Re-Organization, Consolidation, Quality Assurance and the Cost of Space in the Biorepository

Sherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women’s Hospital

Is There a Web-Based Solution to the Challenge of Informed Consent and Re-Consent of Legacy Biobank Samples?

Daniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Tissue Banking, Bioinformatics and EMRs: The Front-End Requirements for Personalized Medicine

K. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

PANEL DISCUSSION: Ensuring Biobank Value through Effective Utilization

Moderators:

Marianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for

Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER

Marianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of

Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

Panelists:

Jeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Sherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women’s Hospital

K. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Daniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Additional Panelists to be Announced

BIOSAMPLES, BIOMARKERS AND CLINICAL TRIALS

FEATURED PRESENTATION :

TRANSLATING PRECISION MEDICINE STRATEGY INTO OUTCOME THROUGH CLINICAL TRIALS

Lillian L. Siu, M.D., FRCPC, Professor, University of Toronto; Medical Oncologist, Princess Margaret Cancer Centre

Obtaining Biospecimens for Correlative Studies in Multi-Centre Lymphoma Clinical Trials

Koren Mann, Ph.D., Assistant Professor, Oncology, Lady Davis Institute for Medical Research, McGill University

Case Study #1: Biospecimen Sciences, Clinical Trials and Precision Medicine: Examples from Our Practice

Michael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

Anthony M. Joshua, MBBS, Ph.D., Staff Oncologist/Affiliate Scientist, Princess Margaret Cancer Centre

TOOLS TO ACCESS BIOSPECIMEN QUALITY

From Research to Clinic: (Pre-)Analytical Variables and Assay Development

Veronique Neumeister, M.D., Laboratory Director, Specialized Translational Services Lab, Department of Pathology, Yale University School of Medicine

Experimental Animal Models to Inform Human Biobanking Practices

Galen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute

Freezing under Pressure: A New Method for Cryopreservation

Nickolas Greer, CSO, Rissali LLC

Microfluidic Evaluation of Red Cells Collected and Stored in Modified Processing Solutions Used in Blood Banking

Dana Spence, Ph.D., Associate Professor, Department of Chemistry, Michigan State University

FEATURED PRESENTATION:

PRE-ANALYTICAL VARIABLES IMPACTING PERIPHERAL BLOOD SAMPLES FOR IMMUNE MONITORING IN MULTICENTER STUDIES

Amit Bar-Or, M.D., FRCPC, Professor, Neurology & Neurosurgery; Director, Experimental Therapeutics Program and Scientific Director, Clinical Research

Unit, Montreal Neurological Institute, McGill University

CASE STUDIES: BIOBANKER/BIOUSER PARTNERSHIPS

Biomedical researchers and drug developers require accessible, highquality biospecimens that allow them to extract reliable and useful data.

Oncology experts, for instance, use patient-derived tumor collections to connect datasets, pinpoint and assess variants within cancer patients

post-diagnosis and zero in on the data that matter when tailoring therapies. Early, strategic collaborations with the biobanks that house

specimens can be mutually beneficial, maximizing the financial and technological investments of the operation managers who collect, store,

annotate and distribute the biological samples (“biobankers”) and supporting the research goals of the scientists who need those samples

(“biousers”) – all to fulfill the promise of personalized medicine.

SPECIALTY BIOBANKS

The Future of iPSCs Biobanking

Jonathan Y.H. Loh, Ph.D., Assistant Professor, Department of Biological Sciences, National University of Singapore, A*STAR Institute of

Molecular and Cell Biology

Biobanking to Improve Cardiac Transplant Outcomes

Dawn E. Bowles, Ph.D., Assistant Professor, Department of Surgery, Division of Surgical Sciences and Co-Director, Duke Human Heart Repository

Planning and Implementing an Institutional Hospital for Children and Women: Ethical and Operational Consideration

Suzanne Vercauteren, M.D., Ph.D., FRCPC, Head, Division of Hematopathology, BC Children’s Hospital and Clinical Assistant Professor,

Pathology and Laboratory Medicine, University of British Columbia

The University Health Network Genito-Urinary (GU) BioBank

Neil Fleshner, M.D., MPH, FRCSC, Chair, Urology, Department of Surgery, University of Toronto; Head, Urology, University Health Network; Director,

GU BioBank, Princess Margaret Cancer Centre

Give Life Twice – An Overview of Canada’s National Public Cord Blood Bank

Heidi Elmoazzen, Ph.D., Director, National Public Cord Blood Bank

Toronto Lung Transplant Biobanking Project, What We Are Collecting

Sassan M. Azad, Project Manager, Clinical, Translational & Biobanking Research Office, Toronto Lung Transplant Program, Toronto General Hospital,

University Health Network

MAINTAINING A QUALITY BIOBANK WITH IT

Progress Is Bringing Together Clinical and Biorepository Data in an Expandable Research Data Repository

Maureen E. Lane, Ph.D., Assistant Professor, Medicine; Director, Hem/Onc Translational Core Laboratory, The Leukemia Biorepository and Personalized

Medicine Center, Weill Cornell Medical College

Data Bank and BioRepository for Translational and Basic Research

Annmarie Nowak, Coordinator & Director, Data Bank and Biorepository, Biobanking Systems Integration Cancer Prevention and Population Science,

Roswell Park Cancer Institute

Promoting Quality Biobanks and Biobank Quality: The CRIP Toolbox and the Metabiobank p-BioSPRE

Christina Schröder, Ph.D., Head, Metabiobanks CRIP, Fraunhofer Institute for Cell Therapy and Immunology

Register by March 20th & Save!

For sponsorship and exhibit sales information, contact:

Carolyn Benton

Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5412

Email: cbenton@healthtech.com

Healthtech.com/Biobanking

 

SOURCE

From: Leaders in Biobanking <kerris@healthtech.com>
Date: Fri, 06 Mar 2015 11:36:31 -0500
To: <avivalev-ari@alum.berkeley.edu>
Subject: Final Agenda Now Available

Read Full Post »

Nature Biotechnology Podcast Archive: 2/2011 to 12/2014

Reporter: Aviva Lev-Ari, PhD, RN

 

 

SOURCE

http://www.nature.com/nbt/podcast/archive.html

Archive

Previous episodes can be accessed here. To download a show to your computer, right click the Download mp3 link and select ‘Save target as/Save link as’ and save the file to your computer or a CD.

      • December 2014: First Rounders:

        Listen now | Download mp3
        Daphne Zohar is the founder, CEO and managing partner at PureTech, a venture creation company with a new approach to building biotechs, and she sits on the board of several life science firms. Her podcast conversation with Nature Biotechnology covers starting her first company (in high school), the usefulness of Bioentrepreneur courses, and women in venture capital.

      • September 2014: First Rounders:

        Listen now | Download mp3
        Mary Tanner details the Amgen-Immunex buyout, defines ‘wildcatting’ and suggests the years in which children most need a parent around the house.

      • August 2014: Focus issue podcast:

        Listen now | Download mp3
        Anthony Davies discusses the past, present and future of stem cell therapies.

      • July 2014: First Rounders:

        Listen now | Download mp3
        Julian Davies takes us through his long research career in Madison, Wisconsin; Paris and Geneva. He also discusses wrecking his motorcycle and how he met his wife.

      • May 2014: First Rounders:

        Listen now | Download mp3
        Leroy Hood talks through the founding of Applied Biosystems, the beginnings of the Human Genome Project and what drew him to mountain climbing.

      • March 2014: First Rounders:

        Listen now | Download mp3
        Nature Biotechnology talked to West about his initial love for physics, scoring the first funding for Geron and the future of regenerative medicine.

      • December 2013: First Rounders:

        Listen now | Download mp3
        Nature Biotechnology spoke to Harvey Berger about developing Iclusig, the difference between managing a patient’s health and running a company, and how a public entity deals with bad news.

      • October 2013: First Rounders:

        Listen now | Download mp3
        George Yancopoulos talks about the scientific foundation at Regeneron, upholding the family name and giving back through teaching.

      • September 2013: First Rounders:

        Listen now | Download mp3
        Una Ryan discusses the biotech East Coast vs. West; life in Oxford, UK; and her initial foray into industry via a job at Monsanto.

      • June 2013: First Rounders:

        Listen now | Download mp3
        William A. Haseltine talks about his time at HGS, the future of genomics in drug discovery and how innovation might be funded going forward.

      • March 2013: First Rounders:

        Listen now | Download mp3
        Henri Termeer discusses his path to Genzyme, the approval of Ceredase and the drawn-out negotiations with eventual acquirer Sanofi.

      • February 2011:

        Listen now | Download mp3
        A roundtable discussion examining venture capital funding levels for innovative science in biotech.

SOURCE

http://www.nature.com/nbt/podcast/archive.html

 

Read Full Post »

Nature Biotechnology Podcast with Daphne Zohar, Founder, CEO and Managing Partner at PureTech

Reporter: Aviva Lev-Ari, PhD, RN

 

First Rounder: Daphne Zohar

Daphne Zohar is the founder, CEO and managing partner at PureTech, a venture creation company with a new approach to building biotechs, and she sits on the board of several life science firms. Her podcast conversation with Nature Biotechnology covers starting her first company (in high school), the usefulness of Bioentrepreneur courses, and women in venture capital.

 

CLICK on AUDIO PLAYER

http://www.nature.com/nbt/podcast/index-2014-12-05.html?WT.mc_id=TWT_NatureBiotech

PureTech Pipeline

Pipeline

Cross disciplinary

“PureTech has the scientific creativity to really go for the big ideas that can be game changers. The team dreams up technologies and then makes them happen

– Dr. Robert Langer, PureTech co-founder,
Senior Partner & Board Member.
PureTech’s programs have attracted several hundred million dollars in outside funding and PureTech has active strategic partnerships with some of the most forward thinking health and technology companies in the world. Several of our programs are at or beyond the stage of human clinical testing, developing technologies poised to disrupt several multi-billion dollar market segments. Explore our pipeline below to learn more about what we’ve created:

  • Discovery & Preclinical
  • Human Clinical Studies
  • Beta
  • Launch

Immunology

Vedanta
Valley of Life

Metabolism

Gelesis

Consumer & Digital

Mandara
Follica
Knode
Enlight Immersive Health
Akili

Neuroscience

Tal
Karuna

Drug Delivery

Entrega

PureTech co-founded but current holdings not significant.

  • Discovery & Preclinical
  • Human Clinical Studies
  • Beta
  • Launch
Fluoro Pharma
AZ Therapies
Mersana
Endra

 

Read Full Post »

« Newer Posts